How Legislation on Decisional Capacity Can Negatively Affect the Feasibility of Clinical Trials in Patients with Dementia
- 80 Downloads
Antipsychotic drugs are widely used to treat behavioural and psychological disturbances associated with Alzheimer’s disease (AD), although only modest evidence from randomized controlled trials supports their efficacy, and increasing evidence from post-marketing surveillance shows serious adverse events associated with their use, including increased mortality. The AdCare study, a non-profit, randomized, placebo-controlled, double-blind, multicentre, pragmatic trial coordinated by the Italian National Institute of Health, aimed to evaluate the long-term safety and efficacy profiles of three atypical antipsychotic drugs (risperidone, olanzapine and quetiapine) and one conventional antipsychotic drug (haloperidol) in treating psychosis, aggression and agitation in outpatients with AD. The study was planned to be carried out in 19 clinical centres and to enrol 1000 outpatients. According to Italian law, in the case where a patient is considered unable to give informed consent, a legal representative designated by the court has to provide it.
Because of difficulties in the informed consent procedure, the study had to be prematurely interrupted. From February 2009 to April 2010, 83 patients gave informed consent to participate in the trial. Fifty-six patients (68%) were included with consent given by a legal representative, while 27 patients (32%) were considered to provide personal informed consent on the basis of the results from a specifically built procedure. Patients and caregivers were offered the opportunity to participate in the trial before the occurrence of behavioural disturbances, in order to provide them with enough time to consider their participation in the study. Twenty-three patients experienced behavioural, clinically relevant symptoms and were randomized to the study drug; all randomized patients except one had consent for inclusion in the study given by legal representatives. After trial interruption, all patients taking an active drug continued treatment with the same molecule in clinical practice.
This study was supported by the Italian Medicines Agency (AIFA) within the independent drug research programme, contract no. FARM68SY5C. The authors have no conflicts of interest to declare.
We thank Eleonora Lacorte for editorial assistance.
AdCare study group: P. Popoli, R. Potenza, M.T. Tebano (Istituto Superiore di Sanità, Roma); F. Giubilei, N. Locuratolo, G. Bruno, E. Piacentini, G. Talarico, M. Gasparini (Università Sapienza, Roma); M.L. Del Re (Ospedale Civile, Pescara); A. Bruni, R. Colao, G. Puccio, S. Curcio, A. Clodimiro (Centro Regionale di Neurogenetica, Lamezia Terme); P. Caffarra, G. Messa, L. Concari, B. Pagliara (Università, Parma); A. Fabbo, P. Zucchi, A. Bonora, M. Veschi (Distretto di Mirandola AUSL, Modena); G. Carbone, R. Ursino, L. Fatica, C. De Bonis (Italian Hospital Group, Guidonia); G. Gainotti, C. Marra, D. Quaranta, M. Zinno (Policlinico Gemelli, Roma); G. Rodriguez, F. Nobili, MP Barbieri, B. Dessi, D. Mazzei, D. Arnaldi, A. Brugnolo (Dipartimento di Neuroscienze Oftalmologia e Genetica-Università, Genova); F. Clerici, C. Mariani, L. Maggiore, S. Pomati (Ospedale Sacco, Milano); A. Padovani, L. Rozzini, M. Zanetti, M. Conti (Ospedali Civili, Brescia); C. Negri Chinaglia, I. Engaddi, D. De Domenico, G. Savorgnan (Pio Albergo Trivulzio, Milano); O. Scarpino, P. Civerchia, A. Raccichini (Neurologia, INRCA, Ancona); L.M. Specchio, R. Goffredo, M.E. Biancardi (Ospedali Riuniti, Foggia); V. Putzu, Y. Araujo, A. Ballisai (Ospedale SS. Trinità, Cagliari); M.R. Piras, R. Cherchi, C.F. Bagella, E. Deiana (Istituto Clinica Neurologica, Sassari); M. Giordano, A. Pineo, T.M. Vitrano Catania (Centro di Riferimento Regionale Demenze Senili-Alzheimer ASP, Palermo); L. Bracco, C. Piccini (Clinica Neurologica I, Firenze); P. Mecocci, F.T. Feliziani, V. Cornacchiola (Università, Perugia); G. Gambina, E. Broggio, F. Sala (Neurologia-Azienda Ospedaliera, Verona).
- 8.Public Health Advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. Silver Spring (MD): US FDA [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetylnformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171.htm [Accessed 2012 Apr].
- 9.Health Canada advises consumers about important safety information on atypical antipsychotic drugs and dementia. Ottawa (ON): Health Canada, 2005 Jun 15 [online]. Available from URL: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/_2005/2005_63-eng.php [Accessed 2012 Apr].
- 10.European Agency for the Evaluation of Medicinal Products (EMEA). Cerebrovascular events and increased mortality in eldery patients with dementia. London: EMEA, 2004.Google Scholar
- 15.Viale D, Mereu RM, Asuni G, et al. Behave-AD-FW Behavioral Pathology in Alzheimer’s Disease Rating Scale: reliability of the Italian version of the scale. G Gerontol 2005; 53: 20–32.Google Scholar
- 16.Izzicupo F, Vanacore N, Galeotti F, et al. Parametri per la valutazione della capacita di esprimere consenso al trattamento e strumenti per la loro misurazione. In: Petrini C, editor. Il Consenso informato al trattamento dei soggetti affetti da demenza; aspetti etici, deontologici e giuridici. Rapporto ISTISAN 2008; 33: 14–22.Google Scholar
- 19.Department of Veterans Affairs. Clinical assessment for competency determination: a practice guideline for psychologist. Milwaukee (WI): Department of Veterans affairs, National Centers for Cost Containment, 1997.Google Scholar
- 24.Kim SYH, Karlawish JHT, Caine ED. Current state of research on decision-making competence of cognitively impaired elderly persons. Am J Ger Psychiatry 2002; 10: 151–65.Google Scholar
- 33.National Bioethics Advisory Commission. Research involving persons with mental disorders that may affect decision-making capacity. Vol. 1. Report and recommendations of the National Bioethics Advisory Commission. Rockville (MD): US Government Printing Office, 1998.Google Scholar
- 35.Landhuis E. AD research participation: informed consent complicates trials, part 2. Subject protection versus research progress: debate continues. Alzheimer Research Forum [online]. Available from URL: http://www.alzforum.org/new/detailprint.asp?id=1868 [Accessed 2012 Apr].
- 36.European Parliament and the Council of the European Union. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products of human use. Official Journal of the European Communities 2001 May 1; L121: 34–44.Google Scholar
- 37.Dementia in Europe Yearbook 2009. Luxembourg: Alzheimer Europe, 2009.Google Scholar